Research Guide · AA-RET-2026-44T
Retatrutide 20mg
GIP / GLP-1 / Glucagon Tri-Agonist — High Concentration
CAS
2381089-83-2
Mol. Weight
4731.3 g/mol
Purity
99.94%
Format
20mg Vial
Overview
Retatrutide is a triple hormone receptor agonist engaging GIP, GLP-1, and glucagon receptors simultaneously. This 20mg high-concentration format supports extended multi-phase research protocols without mid-study vial changes.
Mechanism of Action
Balanced tri-agonism: GLP-1 receptor engagement modulates incretin signaling, GIP receptor activity influences adipose tissue handling, and glucagon receptor agonism drives energy expenditure pathways — a three-axis approach documented in receptor-profiling studies.
Dosing-Study Summary
Phase 2 human clinical trial
1–12 mg, subcutaneous, weekly × 48 weeks
Dose-dependent body-weight reduction reaching ~24% at the highest arm (PubMed #37366315)
In-vitro receptor profiling
Nanomolar range
Confirmed balanced tri-receptor engagement with distinct downstream signaling signatures
Doses shown are reported in cited preclinical / clinical literature for research reference only — not usage recommendations.
Storage & Handling
Store lyophilized at -20°C protected from light. Reconstitute with bacteriostatic water under sterile technique; refrigerate at 2–8°C. Long peptides are aggregation-prone — allow to dissolve gently without vortexing.
Citations
This guide summarizes published scientific literature for laboratory research reference. Alpha Amino compounds are for research use only — not for human or animal consumption. Nothing here constitutes medical or dosing advice.